SCHEMBL1944367

SCHEMBL1944367

Fc1cccc(-c2cnc3sc(NCCc4ccccn4)nn23)c1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FYN P06241 18/20 0.54
MKNK1 Q9BUB5 1/20 0.49
KIT P10721 1/20 0.45
PIM1 P11309 1/20 0.45
FLT3 P36888 1/20 0.45
CDK7 P50613 1/20 0.45
KCNH2 Q12809 1/20 0.45
PIM3 Q86V86 1/20 0.45
HASPIN Q8TF76 1/20 0.45
PIM2 Q9P1W9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944190 0.88 FYN (0.62) FYNMKNK1
SCHEMBL1947634 0.88 FYN (0.52) FYNMKNK1
SCHEMBL1944569 0.87 FYN (0.49) FYNMKNK1
SCHEMBL1944084 0.86 FYN (0.61) FYNMKNK1KITPIM1FLT3
SCHEMBL1944770 0.85 FYN (0.54) FYNMKNK1
SCHEMBL1946356 0.85 FYN (0.55) FYNMKNK1
SCHEMBL1947376 0.85 PIM1 (0.50) FYNMKNK1PIM1
SCHEMBL1945386 0.84 FYN (0.74) FYNMKNK1
SCHEMBL12545019 0.84 FYN (0.67) FYN
SCHEMBL1944052 0.84 FYN (0.66) FYNMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R FYN 1977/4885MKNK1 860/4885KIT 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.